Rigontec – Innate immune system in cancer immuno-therapy

Rigontec was a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, one of the most essential pathways in the innate immune system, as a novel and distinct approach in cancer immuno-therapy to induce both immediate and long-term anti-tumor immunity. The company is a spin-out from University of Bonn.